Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS’ “Potential” NCD List Gets Stakeholder Support, But Questions Remain

This article was originally published in The Gray Sheet

Executive Summary

The device industry and other Medicare stakeholders are generally supportive of CMS' recent move to publicize topics it is considering for future national coverage determinations, though some worry that the agency will use the process to limit patient access to technologies
Advertisement

Related Content

Data Lacking On Proton Therapy Vs. Traditional Radiation For Cancer - AHRQ
Data Lacking On Proton Therapy Vs. Traditional Radiation For Cancer - AHRQ
Debate Stirs Over Medicare Coverage For Proton Therapy In Prostate Cancer
CMS Floats Topics For Possible National Coverage Determinations
CMS Floats Topics For Possible National Coverage Determinations
In Need Of Evidence: Medicare Panel Prioritizes Research Efforts
Advertisement
UsernamePublicRestriction

Register

MT026665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel